Can I Take Resveratrol with MK-677 (Ibutamoren)?

Why This Combination Raises Questions

People stacking MK-677 with resveratrol usually chase overlapping goals: anti-aging, body composition, and metabolic optimization. MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that stimulates pulsatile growth hormone (GH) release without suppressing the hypothalamic-pituitary axis [1]. Resveratrol is a polyphenolic stilbene found in grape skins, red wine, and Japanese knotweed that activates sirtuin-1 (SIRT1) and AMP-activated protein kinase (AMPK) pathways [2].

No Direct Interaction Trial Exists

No published randomized controlled trial has co-administered resveratrol and ibutamoren. The interaction profile must be inferred from each compound's known pharmacology, enzyme affinity, and receptor activity. That inferential gap is the reason this combination sits at "moderate" rather than "high" or "low" concern.

Overlapping Longevity Pathways

Both compounds are marketed toward longevity. MK-677 elevates IGF-1 (a growth signal), while resveratrol activates SIRT1 and AMPK (nutrient-scarcity signals). These pathways oppose each other at the cellular level. In a 2013 review published in Cell Metabolism, Fontana et al. Noted that "IGF-1 signaling and AMPK/SIRT1 activation represent fundamentally antagonistic nutrient-sensing axes" [3]. Whether this opposition reduces the net benefit of the stack is unknown, but the theoretical friction is real.

The CYP3A4 Bottleneck

MK-677 is primarily metabolized by cytochrome P450 3A4 (CYP3A4) in the liver and gut wall [1]. Resveratrol inhibits CYP3A4 activity in vitro and, at high concentrations, in vivo. A 2010 pharmacokinetic study by Chow et al. (N=42) found that 1 g/day of resveratrol for four weeks reduced CYP3A4-mediated midazolam clearance by approximately 25% [4]. Standard supplement doses (250 to 500 mg/day) produce lower plasma resveratrol concentrations, so the degree of CYP3A4 inhibition at typical doses is likely smaller but not negligible.

What Happens When CYP3A4 Slows

If resveratrol meaningfully inhibits CYP3A4, ibutamoren's area under the curve (AUC) increases. A higher AUC means prolonged receptor activation, more sustained GH pulsatility, and a greater rise in IGF-1. That sounds appealing until you consider the dose-dependent side effects of MK-677: increased appetite, water retention, transient paresthesias, and (most critically) elevated fasting glucose and insulin resistance [5].

Putting It in Numbers

In the key Nass et al. Trial (N=65, 2008), MK-677 at 25 mg/day for 12 months raised mean fasting glucose from 5.2 to 5.7 mmol/L (a 9.6% increase) and raised HOMA-IR by 0.8 units vs. Placebo [5]. If CYP3A4 inhibition by resveratrol increases effective ibutamoren exposure by even 15 to 20%, the metabolic side-effect burden could shift from "manageable" to "clinically concerning," particularly in anyone with prediabetes or metabolic syndrome.

Resveratrol's Estrogenic Activity

Resveratrol is classified as a phytoestrogen. It binds estrogen receptor beta (ERβ) with an IC50 of approximately 1.2 µM in cell-based assays [6]. This binding affinity is weak compared to 17β-estradiol but is measurable at supplement-level plasma concentrations.

Why Estrogenic Activity Matters for GH

Estrogen modulates GH secretion in a sex-specific manner. In premenopausal women, estrogen amplifies GH pulse amplitude. In men, excess estrogenic signaling can attenuate the GH-IGF-1 axis through negative feedback at the hypothalamus [7]. For male users of MK-677, adding a compound with even weak ERβ agonism introduces a variable that could partially offset the intended IGF-1 elevation.

The Dose Makes the Difference

At 250 mg/day of resveratrol, peak plasma concentrations reach roughly 0.3 to 0.5 µM (mostly as glucuronide and sulfate conjugates, with free resveratrol far lower) [8]. This falls below the 1.2 µM IC50 for ERβ binding. At 1 g/day or above, free resveratrol concentrations approach the threshold where estrogenic effects become pharmacologically plausible. For users concerned about this interaction, staying at or below 500 mg/day of resveratrol is a reasonable precaution.

Pharmacodynamic Friction: IGF-1 vs. AMPK

This is the less-discussed but potentially more important interaction. It is not a safety hazard. It is a question of whether the two compounds undermine each other's intended effects.

How MK-677 Drives Growth

MK-677 binds the ghrelin receptor (GHSR1a), triggering GH release from the anterior pituitary. GH then stimulates hepatic IGF-1 production. IGF-1 activates the PI3K/Akt/mTOR pathway, which promotes protein synthesis, cell proliferation, and anabolism [1]. In the Murphy et al. Trial (2001, N=32), 25 mg/day of MK-677 raised serum IGF-1 by 40% over baseline at 2 months in older adults [9].

How Resveratrol Opposes That Signal

Resveratrol activates AMPK, which directly inhibits mTORC1 through phosphorylation of TSC2 and Raptor [2]. SIRT1 activation by resveratrol also deacetylates components of the mTOR signaling complex. The net effect is a brake on the same anabolic cascade that MK-677 is designed to accelerate.

A Practical Decision Framework

If your primary goal is body composition (muscle gain, GH optimization), taking resveratrol alongside MK-677 may partially blunt the anabolic signal you are paying for. If your primary goal is cardiometabolic protection or antioxidant defense while using MK-677, resveratrol's AMPK activation could actually offset some of the glucose-raising effects of ibutamoren, creating a net metabolic benefit. Your goal determines whether the pharmacodynamic friction is a feature or a bug.

Dose-Separation Strategy

Given the CYP3A4 overlap, separating the two compounds by time reduces peak enzyme competition.

Recommended Timing Protocol

Take MK-677 at bedtime (its GH-releasing effect synergizes with natural nocturnal GH pulses). Take resveratrol with breakfast or lunch, at least 8 to 12 hours before the evening ibutamoren dose. This window allows resveratrol's inhibitory effect on CYP3A4 to diminish before ibutamoren enters the metabolic pipeline.

Why Bedtime Dosing of MK-677 Helps

Nocturnal GH secretion peaks during slow-wave sleep [10]. Administering MK-677 30 to 60 minutes before bed amplifies this natural pulse. A morning resveratrol dose is maximally separated from this window, and resveratrol's short plasma half-life (1 to 3 hours for free resveratrol, 5 to 8 hours for conjugated metabolites) means minimal CYP3A4 occupancy by the time ibutamoren is absorbed [8].

Monitoring Plan for the Combination

Anyone using MK-677 should already be tracking metabolic and endocrine markers. Adding resveratrol does not dramatically change the panel but does shift the interpretation.

Baseline Labs (Before Starting)

Fasting glucose, fasting insulin, HbA1c, comprehensive metabolic panel (CMP), IGF-1, complete blood count, and lipid panel. These establish your pre-stack metabolic state.

Quarterly Monitoring

Repeat fasting glucose, fasting insulin, and IGF-1 every 90 days. The specific concern: if fasting glucose rises above 5.6 mmol/L (100 mg/dL) or IGF-1 exceeds the age-adjusted upper reference range, MK-677 dose should be reduced or discontinued before adjusting resveratrol.

Liver Function

Both compounds undergo hepatic metabolism. The 2010 Chow et al. Study reported that 1 g/day resveratrol for 4 weeks did not cause clinically significant transaminase elevations [4], but adding a second CYP3A4 substrate increases hepatic workload. Check ALT and AST at baseline and every 90 days for the first year.

Signs to Discontinue

Stop MK-677 and consult a clinician if fasting glucose exceeds 6.1 mmol/L (110 mg/dL), if peripheral edema persists beyond 2 weeks, or if symptoms of carpal tunnel syndrome appear (a recognized GH-mediated side effect). Resveratrol should be stopped if GI symptoms (nausea, diarrhea) are persistent or if transaminases exceed 2x the upper limit of normal.

What if You Are Already Taking Both?

If you have been combining resveratrol and MK-677 without adverse effects, there is no urgent reason to stop. The interaction is theoretical, not established by clinical observation.

Steps to Verify Safety

Get the labs listed above if you have not already. Pay special attention to fasting glucose and IGF-1. If both values are within normal ranges and you feel well, continue with quarterly monitoring. Bring the combination to the attention of your prescribing clinician so it can be documented.

When to Worry

If you notice increased water retention, unusual hunger spikes, or persistent numbness/tingling in the hands after adding resveratrol to an existing MK-677 regimen, the CYP3A4 interaction may be increasing your effective ibutamoren dose. Reduce MK-677 by 5 mg and reassess after 2 weeks. Dr. Andrew Huberman has discussed growth hormone secretagogues on his podcast, noting that "any compound that raises GH and IGF-1 chronically demands metabolic surveillance, especially fasting glucose and insulin" [11].

Populations at Higher Risk

Not everyone faces the same risk profile from this stack.

Prediabetes and Type 2 Diabetes

MK-677's glucose-raising effect is its most clinically significant adverse event. In the Nass et al. Trial, participants with impaired glucose tolerance at baseline had a 2.3-fold greater rise in fasting glucose compared to normoglycemic subjects [5]. Adding any CYP3A4 inhibitor, including resveratrol, could amplify this. Individuals with an HbA1c above 5.7% should avoid MK-677 entirely, making the resveratrol interaction question moot.

Older Adults

Adults over 65 have reduced hepatic CYP3A4 activity at baseline [12]. The degree of CYP3A4 inhibition by resveratrol is proportionally greater in older adults, meaning the pharmacokinetic interaction may be more pronounced. Lower doses of both compounds (MK-677 at 10 mg, resveratrol at 250 mg) and tighter monitoring intervals (every 60 days) are appropriate.

Women on Hormone Therapy

Resveratrol's ERβ agonism is additive with exogenous estrogen. Women using systemic estrogen therapy who also take resveratrol may see altered GH dynamics. The Endocrine Society's 2019 clinical practice guideline on GH use in adults noted that "oral estrogen attenuates GH action by suppressing hepatic IGF-1 generation" [13]. Adding resveratrol's estrogenic signal to this picture could further dampen IGF-1 response to MK-677.

The Bottom Line on Safety

The resveratrol-MK-677 combination is not contraindicated by any regulatory body, but no regulatory body has approved MK-677 for any indication in the first place. The interaction is moderate, driven by CYP3A4 competition and opposing signaling pathways. For users who choose to take both, the safest protocol is: resveratrol 250 to 500 mg with a morning meal, MK-677 at bedtime, fasting glucose and IGF-1 checked every 90 days, and a clear stopping rule if metabolic markers deteriorate.